glp-1 inhibitor DPP4 Inhibitors vs Agonists | June 2021 | Clinical Corner Mechanism of action for GIP,

Individuals with Type 2 Diabetes struggling to maintain blood sugar control A body mass index (BMI) of 30 or higher (obesity) BMI of 27 or higher (which is considered overweight) and at least one health condition related to weight, such as high blood pressure, high cholesterol, or obstructive sleep apnea Patients seeking a doctor-supervised, evidence-based medical weight loss plan Suitable for both men and women under proper medical screening Note : Mounjaro is not for use in patients with a personal or family history of medullary thyroid carcinoma (MTC) or MEN 2 syndrome

2A-B, Supplementary Figure S3A)

Tirzepatide Reduces LV Mass and Paracardiac Adipose Tissue in Obesity-Related Heart Failure

Most state Medicaid programs cover GLP-1 medications when prescribed for Type 2 diabetes, but coverage for obesity or weight loss is far less consistent

It bypasses the digestive system entirely, offering you a potent, bioavailable boost that your body can begin using immediately